KRAS and cancer: Importantly, the mutant-specific nature of these inhibitors enables inhibition of KRAS signaling in KRAS G12C mutant cancer cells while sparing signaling in normal cells, thereby widening the therapeutic window compared with nonmutant selective inhibitors (12, 13).